JANX
Janux Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$885.49M
P/E Ratio
—
EPS
$-1.84
Beta
2.57
52W High
$35.34
52W Low
$12.12
50-Day MA
$14.44
200-Day MA
$18.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $13.73M |
| Gross Profit (TTM) | $-113.92M |
| EBITDA | $-155.00M |
| Operating Margin | -916.00% |
| Return on Equity | -11.70% |
| Return on Assets | -9.44% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $15.47 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | 64.48 |
| EV/Revenue | 2.036 |
| EV/EBITDA | -33.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2178.00% |
| Shares Outstanding | $60.98M |
| Float | $39.20M |
| % Insiders | 6.73% |
| % Institutions | 102.52% |
Historical Volatility
HV 10-Day
33.24%
HV 20-Day
34.17%
HV 30-Day
32.69%
HV 60-Day
36.12%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($40.56 target)
2
Strong Buy13
Buy2
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026